Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DPII: Discovery Partners Int'l -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (30)	10/22/2005 6:14:34 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 111

<I had thought that maybe the Biofrontera acquisition could lead to Pfizer signing on again> Hmmm, with the Biofrontera buy and now the recent sale to Nexus, don't you suppose that management has some kind of strategy in mind? Man, one would hope so! .........The one mistake that PFE could make, would be to give up on research spending! steve

To: Mike McFarland who wrote (30)	11/5/2005 3:53:45 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 111

It looks as though it also goes by microARCS and muARCS. Probably a search for "microarrayed compound screening" snags most. fwiw... ncbi.nlm.nih.gov There may be presentations by two of the inventors here (don't know if they mention uARCS) reedbusinessinteractive.com Dave Burns, PhD, Sr. Project Leader, Biological Screening, Abbott Laboratories David Burns, PhD, is one of the original inventors of the ultra-high-throughput screening technology platform known as µARCS, (licensed to Discovery Partners International) at Abbott Laboratories. He has extensive experience in the design and development of assays for high-throughput screening and other lead identification strategies, and has been in the drug discovery business for 15 years, including a previous stint at Sphinx Pharmaceuticals. Burns received his PhD in biochemistry from Indiana University and was a postdoctoral student at the Duke University Medical Center. He has been a member of the Society for Biological Screening (SBS) since 1995, serving as a session chair and as 2002 Program Co-Chair for the annual SBS Conference & Exhibition. He shared the 2004 SBS PolyPops Foundation Award for the Best Innovation in Microplate Design or Application with Jim Kofron for the µARCS technology. He also currently serves on the SBS Board of Directors. Burns authored more than 50 scientific publications. Mark Schurdak, PhD, Group Leader, Biological Screening, Abbott Laboratories Mark Schurdak, PhD, is currently coordinating high-throughput siRNA screening efforts and leading the high-content screening core group within Abbott’s HTS group. He has been involved with screening operations at Abbott since 1996 where he was part of the group developing assays to screen combinatorial libraries. Schurdak is one of the co-inventors of the µ-ARCS technology, was involved in establishing the affinity selection mass spectrometry technology, and in developing early high-throughput ADME assays at Abbott. He earned his PhD in pharmacology at Baylor College of Medicine in Houston, Texas, after which did postdoctoral training at Hoffman-La Roche studying DNA adduct formation by polycyclic hydrocarbons.